Codix has reaffirmed its commitment to strengthening Nigeria’s healthcare system and advancing regional self-sufficiency with the continued scale-up of local rapid diagnostic test (RDT) production through Colexa Biosensor.
Driven by a strategic vision to reduce reliance on imported medical diagnostics, Codix established Colexa Biosensor in 2023 and Codix Bio in 2025 to position Nigeria as a regional hub for high-quality diagnostic solutions. The initiative represents a significant step toward reinforcing health security in Nigeria and expanding access to reliable diagnostics across Africa.
Colexa Biosensor currently supports Nigeria’s HIV response through the local packaging of the WHO pre-qualified Standard Q HIV 1/2 Rapid Diagnostic Test (RDT) at its Lagos facility.
Approved under the WHO Pre-Qualification Change Notification, Colexa Biosensor remains the only facility in Africa authorized to package a WHO pre-qualified HIV RDT. This designation ensures a dependable, quality-assured local supply of HIV testing kits for national health programs and donor-supported procurement initiatives.
The product has been evaluated and approved by Nigeria’s Ministry of Health and the National AIDS and STI Control Programme (NASCP) and remains listed on the National HIV Testing Algorithm. Its inclusion enables procurement by federal and state government agencies, as well as international partners supporting HIV testing services nationwide.
Local packaging at the Colexa Biosensor facility offers key advantages for implementing partners and donors, including reduced lead times, improved supply continuity, enhanced responsiveness to demand fluctuations, and reduced dependency on imported finished products. These advantages are particularly critical in maintaining uninterrupted HIV testing services across the country.
Quality assurance remains central to operations. The Lagos facility operates under strict, standardized processes aligned with WHO requirements, supported by robust documentation and batch control systems. Continued compliance with WHO pre-qualification standards ensures that locally packaged products meet the same global quality benchmarks as those manufactured at the original production site.
As demand for reliable HIV diagnostics continues, Colexa Biosensor stands ready to support scaled deployment, rapid distribution, and sustainable access to quality-assured testing solutions across Nigeria and the wider region.
Looking ahead, Codix plans to expand exports of its diagnostic products to countries across West and East Africa, reinforcing its commitment to strengthening regional healthcare access, enhancing supply chain resilience, and advancing medical self-sufficiency across the continent.
